Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies
- DOI
- 10.1080/10428194.2026.2699287
- Published
- 2026-07-26
- Container
- Leukemia & Lymphoma
- Publisher
- Informa UK Limited
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1080/10428194.2026.2699287,
title = {Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies},
author = {Norbert Vey and Olga Salamero and Ashish Bajel and Pau Montesinos and Naval Daver and Thomas Prebet and Ollivier Legrand and Christian Récher and Aline Maillard and Agnès Hemon and Valerie de Burgat and Annette Ervin-Haynes and Alberto Broniscer and Andrew H. Wei},
year = {2026},
journal = {Leukemia \& Lymphoma},
doi = {10.1080/10428194.2026.2699287},
url = {https://doi.org/10.1080/10428194.2026.2699287}
}RIS
TY - JOUR TI - Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies AU - Norbert Vey AU - Olga Salamero AU - Ashish Bajel AU - Pau Montesinos AU - Naval Daver AU - Thomas Prebet AU - Ollivier Legrand AU - Christian Récher AU - Aline Maillard AU - Agnès Hemon AU - Valerie de Burgat AU - Annette Ervin-Haynes AU - Alberto Broniscer AU - Andrew H. Wei PY - 2026 JO - Leukemia & Lymphoma DO - 10.1080/10428194.2026.2699287 UR - https://doi.org/10.1080/10428194.2026.2699287 ER -
APA
Vey, N., Salamero, O., Bajel, A., Montesinos, P., Daver, N., Prebet, T., Legrand, O., Récher, C., Maillard, A., Hemon, A., Burgat, V. D., Ervin-Haynes, A., Broniscer, A., & Wei, A. H. (2026). Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies. Leukemia & Lymphoma. https://doi.org/10.1080/10428194.2026.2699287
Source records
- crossref · retrieved 2026-09-26T06:35:10.224Z